Markets›Health care›GILD

Gilead Sciences

GILD
150.93
+1.24 (+0.83%)
Closing price for Sep 25, 2026 from Polygon.io

Valuation

Market value187.15B
Enterprise value210.21B
Price to earnings (P/E)Not meaningful (loss)
Price to sales6.1
Price to book15.8
Free cash flow yield6.9%

Profitability (last 12 months)

Revenue30.46B
Net income-3.24B
Gross margin79.6%
Operating margin-8.2%
Net margin-10.6%
Return on equity-27.4%
Return on assets-6.6%

Growth (last fiscal year, FY 2025)

Revenue growth+2.4%
EPS growth+1,684.2%

Balance sheet (latest quarter)

Cash and equivalents3.18B
Total debt26.25B
Debt to equity2.22
Current ratio1.27

Per share and dividends

EPS, diluted (last 12 months)-2.67
Shares outstanding1.24B
Dividends paid (last 12 months)3.25
Dividend yield2.15%

Trading

Price150.93
52-week high157.29
52-week low108.46
1-year price change+34.02%
Average volume (3 months)6.38M
Beta against the S&P 500 (1 year)0.34

Calculated from Gilead Sciences's SEC filings (latest quarter ending Jun 30, 2026) and the price above. "Last 12 months" adds up the four most recent quarters. Beta compares one year of daily returns with the S&P 500 (SPY). Dividends from Polygon.io or Nasdaq.